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Background: Despite overall improvements in cardiovascular-disease therapies and outcomes, medication nonadher-
ence remains an important barrier to effective secondary prevention of atherothrombotic disease.
Hypothesis: Long-term medication adherence in outpatients with stable atherothrombotic disease is impacted by
demographic and clinical factors.
Methods: We examined data from the prospective international Reduction of Atherothrombosis for Continued Health
(REACH) Registry. Analyses were derived from 25 737 patients with established atherothrombotic disease with complete
adherence data at enrollment and at year 4. Adherence was deﬁned as patients’ self-report of taking medications based
on class I American College of Cardiology/American Heart Association guidelines for secondary prevention as deﬁned,
including antiplatelet agents, statins, and antihypertensive medications.
Results: Among patients with atherothrombotic disease, 12 500 (48.6%) were deemed adherent to guideline-
recommended medications. Adherent patients were younger, white, and had less polyvascular disease. Hispanic
and East Asian patients were less likely to be adherent as compared with white patients (odds ratio [OR]: 0.72, 95%
conﬁdence interval [CI]: 0.59-0.88; and OR: 0.67, 95% CI: 0.53-0.83, respectively). Patients who had a nonfatal MI or
underwent coronary angioplasty/stenting during follow-up were more likely to be adherent compared with patients
without these events (OR: 1.73, 95% CI: 1.25-2.38; and OR: 2.15, 95% CI: 1.72-2.67, respectively). On the other hand,
nonfatal stroke during follow-up was inversely associated with adherence (OR: 0.77, 95% CI: 0.61-0.97).
Conclusions: Using a large international registry of outpatients with atherothrombotic disease, we found that age,
region, race/ethnicity, and incident cardiovascular eventswere predictive of long-termguideline adherence for secondary
prevention, suggesting that certain patient groups may beneﬁt from targeted interventions to improve adherence.
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Introduction
Despite compelling evidence that medical therapy for
atherothrombotic disease improves clinical outcomes,1–3
medication nonadherence remains an important barrier
to secondary prevention.2,4–7 Medication nonadherence
is associated with both higher costs and adverse clinical
outcomes.1,5,8 Ensuring adherence to evidence-based drug
regimens remains a central public-health priority.
Several medications have been demonstrated in large
clinical trials to be efficacious in reducing cardiovascular
(CV) endpoints of death and recurrent events.3,9–11 Among
these, secondary prevention through the long-term use of
antiplatelet agents, statins, and antihypertensives has been
shown to improve outcomes, reduce readmissions, and
decrease overall health care costs.2,12,13
Medication nonadherence has been linked to patient,
disease, and system factors.1,14,15 However, studies have
largely focused on in-hospital and postdischarge adherence
to CV medications. Few studies have specifically explored
long-term medication-adherence patterns for patients with
stable atherothrombotic disease at an international level,
and, specifically, which factors predict adherence.
Methods
The global Reduction of Atherothrombosis for Continued
Health (REACH) registry recruited 69 055 consecutive
patients from 44 countries in outpatient clinical settings. The
methods of the REACH Registry have been well described
in prior publications.16–18 Briefly, patients age >45 years
with ≥3 risk factors for atherosclerosis, and patients with
established cerebrovascular disease (documented ischemic
stroke or transient ischemic attack), coronary artery disease
(stable angina, unstable angina, history of percutaneous
coronary intervention, history of coronary artery bypass
grafting [CABG] or previous myocardial infarction [MI]),
and peripheral arterial disease (intermittent claudication,
ankle-brachial index <0.9 or prior intervention), were
eligible for enrollment. All participants provided informed
consent, and the ethics committees in each country
approved the study.
Patient follow-up was conducted at years 1, 2, 3, and 4
after enrollment. Patients were enrolled between 2003 and
2004 and followed up to 2008. Participating physicians were
asked to provide data on subjects’ clinical outcomes and
medication use.
Study Variables
Primary Outcome: Adherence was defined as meeting class
I American College of Cardiology/American Heart Associ-
ation guidelines for secondary prevention in patients with
stable atherothrombotic disease.19,20 Data relating to med-
ication use were patient self-reported at the time of study
visit and collected centrally via use of a standardized inter-
national case-report form. In patients with a previous history
of a cerebrovascular disease or peripheral arterial disease,
complete adherence included the use of ≥1 antiplatelet
agent (defined as aspirin or other antiplatelet agent), a statin
and/or other lipid-lowering agent, and ≥1 antihypertensive
medication if blood pressure was documented as >140/90
mm Hg at the initial visit or >130/80 mm Hg in a patient
with diabetes mellitus or chronic kidney disease. For eligi-
ble patients, antihypertensive-agent adherence was defined
as use of either angiotensin-converting enzyme inhibitors,
angiotensin II receptor antagonists, β-blockers, calcium
channel blockers, diuretics, nitrates, or other antihyper-
tensive agents. For patients with coronary artery disease,
adherence was defined as above in addition to the concomi-
tant use of a β-blocker. Medication use was assessed at time
of enrollment and at each year of follow-up. Nonadherence
was defined as failure to adhere to any of the recommended
medications.
Covariates: We explored the association between patient-
level factors and adherence at baseline and at 4 years of
follow-up. Predictors included patient age as a continuous
variable and sex. Attained educational level was defined at
baseline based on the number of years of formal education
completed, defined by 4 categories: 0 to 8 years, 9 to 12
years (or high school), trade or technical school, or univer-
sity or college. Race/ethnicity was defined by self-report.
Participants were categorized as white, Hispanic, East
Asian, South Asian, black, or other. Employment status was
characterized as full-time, part-time, unemployed, retired,
incapacitated, or other according to self-report at time of
enrollment.
Additional covariates included region (North America,
Latin America, Western Europe, Eastern Europe, Middle
East, and Asia, including Japan). Clinical variables were
smoking status (former, current, or never smoker), diabetes
mellitus, body mass index, and polyvascular disease vs
single vascular disease.
We also explored the association between incident CV
events, including myocardial infarction (MI), coronary
artery bypass grafting, coronary angioplasty or stenting, and
stroke with adherence to evidence-based medical therapies
for secondary prevention.
Statistical Analysis
Analyses were restricted to patients who were eligible
for the 4-year follow-up study, defined as patients who
completed ≥1 postbaseline follow-up visit and who were
enrolled at centers that agreed to participate in the 4-
year study. Patients with missing data for the 4-year
follow-up study (defined as patient attending visit or death
recorded by investigator) and patients without established
atherothrombotic disease were excluded from the final anal-
yses. Continuous variables are expressed as means± SD;
categorical variables are expressed as frequencies and
percentages.
In a secondary analysis, the study sample was restricted
to the US population eligible for follow-up at 4 years
(n= 7210).
To compare categorical variables, χ2 tests of indepen-
dence were used; 2-sided t tests were used for continuous
variables. Multivariate logistic regression models were con-
ducted to explore the relationship between covariates and
adherence at 4 years.
We used SAS version 9.2 (SAS Institute Inc., Cary, NC)
for all analyses. All reported P values are 2-tailed, and values
<0.05 were considered statistically significant.
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Results
Analyses were derived from 25 737 patients with established
atherothrombotic disease who had adherence data at enroll-
ment and at year 4 (Figure 1). At baseline, 12 500 (48.6%)
received all classes of medications and were thus deemed
complete guideline-adherent. The baseline characteristics
of the study sample are shown in Table 1. Fully adherent
patients were likely to be younger, have less polyvascular
disease, be of white race, and report full-time employment
as compared with nonadherent patients. Greater adherence
was observed in North America, Europe, and the Middle
East, whereas participants from Latin America and Asia
were less likely to be complete guideline-adherent.
Table 2 describes adherence by medication category
at each year of follow-up. Patients reported the highest
adherence rates for antihypertensive agents followed by
antiplatelet drugs, with similar rates of adherence during
each year of follow-up.
In unadjusted analyses, predictors of complete adherence
at 4 years of follow-up included younger age, male
sex, higher educational attainment, full-time employment,
geographic region, body mass index, polyvascular disease,
smoking, and Hispanic, East Asian, and other Asian
ethnicity (Table 3). As compared with patients in North
America, patients from Latin America and Asia were
less likely to be complete guideline-adherent at 4 years.
Similarly, nonfatal incident MI, coronary artery bypass
grafting, and coronary angioplasty were strongly associated
with full medication adherence, whereas incident stroke
was inversely associated with adherence. On multivariate
analyses, younger age, region, polyvascular disease,
Hispanic and East Asian ethnicity, and current smoking
status remained predictive of nonadherence. As compared
Figure 1. Flow of diagram of study participants.





n= 13 237 P Valuea
Age, y, mean (SD) 66.3 (9.7) 68.7 (9.8) <0.0001
Male sex, n (%) 8612 (48.90) 8999 (51.10) 0.1146
DM, n (%) 4407 (48.93) 4600 (51.07) 0.4312
PVD, n (%) 1975 (41.30) 2807 (58.70) <0.0001
BMI, kg/m2, mean (SD) 28.1 (5.0) 27.1 (5.1) <0.0001
Region, n (%) <0.0001
North America 3861 (53.55) 3349 (46.45) <0.0001
Latin America 371 (45.47) 445 (54.53) 0.0096
Western Europe 4456 (52.56) 4022 (47.44) <0.0001
Eastern Europe 1923 (51.51) 1810 (48.49) 0.0644
Middle East 206 (64.98) 111 (35.02) <0.0001
Asia 1683 (32.47) 3500 (67.53) <0.0001
Smoking status, n (%) 0.0009
Former 5549 (50.11) 5524 (49.89) 0.8122
Current 1730 (47.45) 1916 (52.55) 0.0021
Never 4925 (47.86) 5365 (52.14) <0.0001
Race/ethnicity, n (%) <0.0001
White 8077 (52.86) 7204 (47.14) <0.0001
Hispanic 402 (44.08) 510 (55.92) 0.0003
East Asian 1236 (29.58) 2942 (70.42) <0.0001
South Asian 119 (53.13) 105 (46.88) 0.3496
Other Asian 629 (47.98) 682 (52.02) 0.1433
Black 278 (52.06) 256 (47.94) 0.3411
Other 512 (55.96) 403 (44.04) 0.0003
Educational attainment, n (%) <0.0001
0–8 years 3902 (48.18) 4196 (51.82) 0.0011
9–12 years 3576 (47.44) 3962 (52.56) <0.0001
Trade/technical 2147 (51.30) 2038 (48.70) 0.0920
University 2319 (50.78) 2248 (49.22) 0.2934
Employment status, n (%) <0.0001
Full time 2450 (53.96) 2090 (46.04) <0.0001
Part time 799 (50.54) 782 (49.46) 0.6690
Unemployed 660 (38.35) 1061 (61.65) <0.0001
Retired 7474 (48.23) 8024 (51.77) <0.0001
Incapacitated 680 (48.99) 708 (51.01) 0.4523
Other 342 (44.71) 423 (55.29) 0.0034
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n= 13 237 P Valuea
Antiplatelet agents, n (%)
ASA 10 725 (57.60) 7894 (42.40) <0.0001
Other 4231 (58.22) 3036 (41.78) <0.0001
Lipid-lowering agents, n (%)
Statins 11 774 (66.30) 5984 (33.70) <0.0001
Other 1653 (62.40) 996 (37.60) <0.0001
CV agents, n (%)
CCBs 3682 (41.89) 5107 (58.11) <0.0001
β-Blockers 10 046 (74.29) 3477 (25.71) <0.0001
Nitrates/other antianginal
agents
3593 (48.50) 3815 (51.50) 0.8794
Diuretics 4809 (50.11) 4788 (49.89) 0.0001
ACEIs 6386 (53.84) 5476 (46.16) <0.0001
ARBs 2511 (47.92) 2729 (52.08) 0.3239
Other antihypertensives 907 (44.75) 1120 (55.25) 0.0004
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; ASA, acetylsalicylic acid (aspirin); BMI,
body mass index; CABG, coronary artery bypass surgery; CCB, calcium
channel blocker; CV, cardiovascular; DM, diabetes mellitus; PVD,
polyvascular disease; SD, standard deviation.
aP values were derived using the independent sample t test for
continuous variables and the χ2 test for categorical values.















Baseline 48.57 85.80 73.83 99.11 64.13
Year 1 49.31 85.86 74.28 97.92 65.25
Year 2 48.73 85.35 74.92 97.64 65.23
Year 3 46.70 84.32 75.63 97.16 65.02
Year 4 47.45 84.20 76.69 96.97 65.32
aDefined as being on ≥1 agent in each class at enrollment and each
year of follow-up. bβ-Blocker adherence rates are based on patients
with coronary artery disease.
with patients who did not experience CV events during
follow-up, incident coronary angioplasty and nonfatal MI
were predictive of complete guideline adherence (odds
ratio [OR]: 2.15, 95% confidence interval [CI]: 1.72-2.67;
and OR: 1.73, 95% CI: 1.25-2.38, respectively), whereas
incident nonfatal stroke was associated with a lower odds of
adherence (OR: 0.77, 95% CI: 0.61-0.97).
In a secondary analysis restricted to participants in
the United States eligible for 4-year follow-up with stable
atherothrombotic disease (n= 7210), there was a total of
213 Hispanic and 115 East Asian participants. Hispanic
race/ethnicity as compared with white race was associated
with a lower likelihood of complete medication adherence
(OR: 0.71, 95% CI: 0.52-0.98). However, East Asian
race/ethnicity was no longer associated with adherence
(OR: 1.10, 95% CI: 0.73-1.66).
Discussion
Using an international prospective registry of patients
with a broad spectrum of established atherothrombotic
disease, we found that <50% of eligible patients were
fully adherent with cardioprotective drug regimens over
a 4-year study observation period. We identified several
important independent predictors of long-term adherence
to secondary prevention therapies. Complete adherence
was associated with younger age and geographic region.
Hispanic and East Asian patients were less likely to
be adherent at 4 years of follow-up. We found that
patients with polyvascular disease were less adherent as
compared with those with single vascular disease, and
that current smokers were less likely to be adherent as
compared with nonsmokers. On the other hand, incident
MI and coronary angioplasty were strongly associated with
increased adherence. Notably, patients with incident stroke
were less likely to be adherent.
Our findings are consistent with and complementary
to prior studies, which have documented the importance
of both clinical and demographic variables on patient
adherence.1,4,8,14,15,21,22 Similar to other studies,23–25 age
influenced complete guideline adherence, with younger
patients reporting greater complete guideline adherence.
Older adults are more likely to have more total medications
prescribed and are less likely to live independently,
both of which are important predictors of medication
nonadherence.6 We also found that Hispanic and East
Asian participants were less likely to be adherent at 4
years of follow-up as compared with non-Hispanic whites.
Given the growing problem of health care disparities in
cardiovascular disease,26 our finding that certain racial and
ethnic groups have lower levels of adherence warrants
attention. Medication nonadherence may in fact be an
important contributor to the persistent gap in CV outcomes
for certain racial/ethnic populations.
Similarly, it is likely that geographic region is driving
some of the disparity in adherence for Hispanic and East
Asian ethnic groups. The Prospective Urban Rural Epidemi-
ological (PURE) study showed similar geographic variation
in rates of self-reported adherence to recommended
therapies for secondary prevention, with the lowest adher-
ence rates in low-income countries.27 Statins and other
medications are particularly costly in developing countries,
such as in Latin America, which may limit adherence. There
may also be geographic differences in prescribing patterns
by providers based on differences in physician perceptions
of the risks and benefits of certain drug classes, such as
antiplatelet therapy and statins, particularly in East Asian
countries.
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Table 3. Crude and Adjusted Logistic Regression Models of Medication Adherence
Unadjusted Models Adjusted Models
Predictors OR (95% CI) P Value OR (95% CI) P Value
Male sex 1.11 (1.05-1.17) <0.0001 1.04 (0.98-1.12) 0.2312
Age, ya 0.97 (0.97-0.98) <0.0001 0.97 (0.97-0.98) <0.0001
Region (ref=North America) <0.0001 <0.0001
Latin America 0.67 (0.57-0.77) <0.0001 0.78 (0.63-0.96) 0.0216
Western Europe 1.05 (0.99-1.12) 0.1271 0.92 (0.85-1.00) 0.0403
Eastern Europe 1.06 (0.98-1.12) 0.1449 0.95 (0.86-1.05) 0.2920
Middle East 1.50 (1.19-1.89) 0.0005 1.39 (1.05-1.83) 0.0197
Asia 0.45 (0.41-0.48) <0.0001 0.49 (0.40-0.61) <0.0001
Race/ethnicity (ref=white) <0.0001 <0.0001
Hispanic 0.59 (0.51-0.67) <0.0001 0.72 (0.59-0.88) 0.0015
East Asian 0.39 (0.37-0.42) <0.0001 0.67 (0.53-0.83) 0.0004
South Asian 0.99 (0.76-1.29) 0.9649 1.30 (0.95-1.78) 0.0988
Other Asian 0.71 (0.63-0.79) <0.0001 0.99 (0.80-1.23) 0.9089
Black 0.85 (0.72-1.01) 0.0697 0.93 (0.76-1.15) 0.5125
Other 1.09 (0.95-1.25) 0.2031 1.01 (0.87-1.18) 0.8825
Attained educational level (ref= 0–8 years) 0.0001 0.9872
9–12 years 0.95 (0.89-1.01) 0.1012 1.01 (0.94-1.09) 0.7764
Trade/technical 1.11 (1.03-1.20) 0.0060 1.00 (0.92-1.10) 0.9401
University 1.07 (1.00-1.15) 0.0651 1.00 (0.91-1.09) 0.9324
Employment status (ref= full time) <0.0001 0.1032
Part time 0.83 (0.74-0.94) 0.0019 1.04 (0.91-1.19) 0.5879
Unemployed 0.59 (0.53-0.66) <0.0001 1.10 (0.96-1.27) 0.1679
Retired 0.77 (0.72-0.82) <0.0001 1.07 (0.97-1.17) 0.1605
Incapacitated 0.87 (0.77-0.98) 0.0210 0.90 (0.78-1.04) 0.1496
Other 0.71 (0.61-0.83) <0.0001 1.17 (0.97-1.41) 0.0973
BMI, kg/m2a 1.03 (1.03-1.04) <0.0001 1.00 (1.00-1.01) 0.2228
Smoking status (ref= never) 0.0163 0.0870
Former 1.07 (1.02-1.13) 0.0090 1.00 (0.94-1.07) 0.9346
Current 1.08 (1.01-1.17) 0.0386 0.91 (0.83-1.00) 0.0486
DM (ref= no) 1.00 (0.95-1.05) 0.9577 1.06 (1.00-1.13) 0.0591
PVD (ref=SVD) 0.70 (0.65-0.74) <0.0001 0.69 (0.64-0.74) <0.0001
Incident CV events
CABG 1.68 (1.21-2.34) 0.0019 1.20 (0.82-1.77) 0.3465
Coronary angioplasty/stenting 2.30 (1.91-2.76) <0.0001 2.15 (1.72-2.67) <0.0001
Nonfatal MI 2.05 (1.58-2.65) <0.0001 1.73 (1.25-2.38) 0.0009
Nonfatal stroke 0.74 (0.61-0.91) 0.0041 0.77 (0.61-0.97) 0.0258
Abbreviations: BMI, body mass index; CABG, coronary artery bypass surgery; CI, conﬁdence interval; CV, cardiovascular; DM, diabetes mellitus; MI,
myocardial infarction; OR, odds ratio; ref, reference; PVD, polyvascular disease; SVD, single vascular disease.
aPer 1-unit increase.
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In a secondary analysis, we attempted to further control
for the effect of geographic region on our findings
by restricting the study sample to the United States;
Hispanic ethnicity remained significantly predictive of
lower medication adherence, suggesting an independent
association between Hispanic ethnicity and medication
adherence. Another possible explanation is that certain
racial/ethnic statusmay be linkedwith lower understanding
of the benefits of continued medication adherence. A study
by Roth and colleagues found that black and Hispanic
patients had significantly higher rates of medication-related
problems and overall higher rates of nonadherence.28
Adverse cultural beliefs about the perceived benefits of
medications and poor provider-patient relationships have
alsobeen cited as reasons for reducedmedication adherence
among certain patient groups.5,29,30
Interestingly, we found a strong association between
incident CV events and long-term adherence. Evidence is
mixed about adherence to therapies after a hospitalization
for acute coronary syndromes.22,25,31 It is likely that
patients with an incident event, such as an MI or
angioplasty/stenting, will have additional opportunities for
medication-adherence reinforcement. Alternatively, patients
who have undergone these procedures may have fewer
ischemic symptoms and may therefore perceive less need
of adherence to prescribed medications. After adjusting
for comorbidities, we found that patients who experienced
a nonfatal MI or required coronary angioplasty with or
without stent placement were more likely to be fully
adherent during follow-up, whereas patients who suffered
from an incident stroke were less likely to be adherent.
One could speculate that stroke patients are more likely to
suffer from cognitive and physical deficits that may impede
complete adherence. Recent studies have suggested that
posttraumatic stress disorder (PTSD) may partially explain
the high rates of medication nonadherence among stroke
survivors.32,33 Stroke survivors who suffer from PTSD may
be more likely to avoid medications because the drugs may
serve as reminders of their triggering event. Also, PTSD
has been independently linked with cognitive dysfunction,
which may in turn lead to medication nonadherence.34
Alternatively, it is possible that stroke patients may have
contraindications for certain therapies that we could not
account for in our analyses. Because patients with a history
of a stroke are at especially high risk for recurrent stroke and
other CV events, these patients may benefit from additional
resources, such as rehabilitation and case managers, to
ensure adequate medication adherence.
To improve complete guideline adherence for secondary
prevention of CVD, some have advocated the use of a
polypill.35 TheUseof aMultidrugPill inReducingCardiovas-
cular Events (UMPIRE) trial used a fixed-dose combination
of aspirin, a statin, and 2 blood pressure–lowering agents to
improve guideline-recommended adherence for secondary
prevention of CVD.36 Preliminary results from this trial
demonstrated that a polypill was associated with a 33%
increase in adherence over a 15-month period.37 Perhaps
such approaches may be particularly useful in reducing
the observed geographic guideline-adherence differences
between low-income and high-income countries, as a polyp-
ill would be associated with reduced dispensing costs of
multiple medications. Government subsidies of such fixed-
dose combination pills may also improve adherence. Addi-
tionally, patients deemed at high risk for nonadherence,
such as the elderly and stroke patients, may benefit from a
simplified medical regimen of a single daily pill.
Several limitations warrant mention. Only a subset of
the total population was eligible for the 4-year follow-up.
We defined adherence based on physician and patient
self-report. We did not have access to direct methods,
such as observed therapy or measurement of biological
markers of the drugs in the blood. However, direct methods
are usually not practical in the clinical setting. Self-report
methods may be biased, although we expect this finding
to be nondifferential between comparison groups. Gehi
and colleagues found that patient self-report of medication
nonadherence was strongly correlated with adverse CV
events.38 We were not able to account for medication side-
effects or other important contributors to nonadherence.
Similarly, selection bias for both patients and physicians
is inherent in registry data, although this is likely to
overestimate adherence rates.
This study has several important strengths. First, the
study’s large size and international representation increase
its external validity. Our findings are applicable to a
broad spectrum of outpatients with stable atherothrombotic
disease followed longitudinally. Most studies on medication
adherence have focused on in-hospital and post–hospital
discharge adherence and have not explored long-term
follow-up in the outpatient setting.
Our study highlights the importance of ascertaining
medication adherence at each clinic visit. Recognizing
patient-level characteristics of poor adherence is useful to
help physicians and medical providers identify patients who
may benefit themost from targeted interventions to improve
adherence.
Conclusion
Using a large, international prospective registry of stable
outpatients with atherothrombotic disease, we found that
age, race/ethnicity, region, and incident CV events were
strong, independent predictors of long-term adherence with
medications. These findings suggest that certain patient
groups may benefit from targeted interventions to improve
adherence.
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